NCT02929979.

Study name	Cognitive remediation for alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD).
Methods	Randomised, triple‐blind, factorial assignment controlled trial
Participants	Inclusion criteria: Veteran Aged 18–65 years Meet DSM‐5 diagnostic criteria for current AUD Meet DSM‐5 criteria for current PTSD Willing to perform daily home‐based computer exercises for 6 weeks Exclusion criteria: History of, or current, psychotic disorder or schizophrenia Current scheduled (i.e. daily) prescribed use of cognitive enhancers (e.g. memantine) or stimulants (e.g. methylphenidate) that may enhance cognitive performance Current severe TBI (DoD TBI Screen 2) Any type of dementia (MMSE < 24), delirium or medical illnesses associated with potential cognitive issues (HIV, hypothyroidism, B12 deficiency) Any level of mental retardation (WTAR) Limited ability to speak/read/write/understand English (WTAR) Inadequate vision or hearing Active suicidal/homicidal intent Self‐report and collateral history from medical record/primary care physician/outpatient addiction treatment team will be used as necessary to determine inclusion and exclusion. Suicidal and homicidal intent will be assessed in the context of a structured clinical interview. In the unlikely event that respondents endorse active intent they will be referred immediately for treatment and will be excluded from the current study
Interventions	Experimental arm Cognitive training Participants complete 22.5 hours of cognitive training exercises over 6 weeks (training 5 times a week) using an app‐based program, BrainHQ. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules. Comparator arm Placebo control Participants play a rotating set of commercial computer games at the same dose and frequency as the cognitive training.
Outcomes	Time points for assessment: baseline, 6 weeks, and 3 months Primary outcomes: neuropsychological assessment (WAIS‐IV, TMT, AAT, HVLT, BVMT‐R, WAIS‐IV WMI, CPT‐II, CWIT, WCST, IGT, DDT, Tower Test (DKEFS)) Secondary outcomes: alcohol use (TLFB), functional status (IPF), PTSD symptom severity (PCL‐M)
Starting date	1 January 2015
Contact information	Adrienne Julie Heinz VA Palo Alto Health Care System, CA
Notes	NCT02929979